Article
Patient and Healthcare Professional Experience with Fixed-Dose Subcutaneous Pertuzumab and Trastuzumab (PHESGO) in a High-Volume Oncology Center in Vietnam: A Real-World Study from a Resource-Constrained Setting
2026-08-31
Abstract excerpt
<title>Abstract</title> <p> Background Fixed-dose subcutaneous pertuzumab and trastuzumab (PHESGO®) has been shown to provide clinical efficacy comparable to intravenous (IV) administration while substantially reducing treatment time. However, real-world evidence regarding patient and healthcare professional (HCP) satisfaction remains limited, particularly in low- and middle-income countries (LMICs), where opti...
Identifiers and source
- Literature Corpus work
- cb92c6e6-34ec-513e-a549-acb5026b1a50
- DOI
- 10.21203/rs.3.rs-10326326/v1
